Results · Jul-Sep 2025 · filed 13 Nov 2025
3B BlackBio Dx Q2 FY26 results
Sales grew 16% to ₹33.9 crore from ₹29.1 crore in Jul-Sep 2024.
Operating profit fell 9% to ₹14.7 crore, an operating margin of 43.5% (down 12.0 points from a year ago).
Net profit grew 1% to ₹15 crore from ₹14.9 crore in Jul-Sep 2024.
Against Apr-Jun 2025: sales +52%, net profit +19%.
Get 3B BlackBio Dx's next results & call in your inbox, the day they're filed.
Free. One short email on the days it files or its shares make a big move, nothing on other days. Unsubscribe in one click.
Jul-Sep 2025 vs a year ago
| ₹ crore | Jul-Sep 2025 | Jul-Sep 2024 | Change |
|---|---|---|---|
| Sales | 33.9 | 29.1 | +16% |
| Operating profit (EBITDA) | 14.7 | 16.2 | −9% |
| Operating margin | 43.5% | 55.5% | −12.0 pts |
| Net profit | 15.0 | 14.9 | +1% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
Filings that week
- 20 Nov 2025Vigilance Awareness Week 2025
- 19 Nov 2025Announcement under Regulation 30 (LODR)-Newspaper Publication
- 14 Nov 2025Announcement under Regulation 30 (LODR)-Newspaper Publication
- 13 Nov 2025Announcement under Regulation 30 (LODR)-Investor Presentation
- 13 Nov 2025Board Meeting Outcome for Outcome Of Board Meeting
- 13 Nov 2025Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30Th September,2025
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.